Recommendation 7

The Committee concludes that the Agreement does not introduce significant changes to India’s intellectual property regime that are likely to support growth in UK pharmaceutical exports. At the same time, the Committee recognises India’s role as a major producer of generic medicines and the importance of retaining some flexibility within its IP framework. The Committee welcomes the establishment of the Working Group on Intellectual Property established under the Agreement. (Conclusion, Paragraph 64)